Media coverage about PDL BioPharma (NASDAQ:PDLI) has been trending somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. PDL BioPharma earned a media sentiment score of 0.08 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 44.6275639199833 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
PDL BioPharma (PDLI) traded up $0.04 on Monday, reaching $2.79. The company had a trading volume of 955,400 shares, compared to its average volume of 1,173,331. PDL BioPharma has a fifty-two week low of $1.96 and a fifty-two week high of $3.55. The company has a market capitalization of $425.98, a price-to-earnings ratio of 5.58 and a beta of 0.46. The company has a quick ratio of 3.10, a current ratio of 3.16 and a debt-to-equity ratio of 0.14.
PDL BioPharma (NASDAQ:PDLI) last released its earnings results on Thursday, November 2nd. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.01. PDL BioPharma had a return on equity of 9.20% and a net margin of 24.51%. The business had revenue of $62.75 million for the quarter, compared to analyst estimates of $61.86 million. During the same quarter in the prior year, the company posted $0.08 earnings per share. PDL BioPharma’s revenue was up 17.0% on a year-over-year basis. equities research analysts anticipate that PDL BioPharma will post 0.67 earnings per share for the current year.
PDL BioPharma declared that its Board of Directors has authorized a share repurchase program on Monday, September 25th that allows the company to buyback $25.00 million in outstanding shares. This buyback authorization allows the biotechnology company to reacquire shares of its stock through open market purchases. Shares buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.
A number of analysts have recently commented on PDLI shares. ValuEngine upgraded PDL BioPharma from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. Cowen restated a “hold” rating and issued a $3.00 price target on shares of PDL BioPharma in a report on Friday, October 27th. BidaskClub lowered PDL BioPharma from a “hold” rating to a “sell” rating in a report on Saturday, January 6th. Finally, Zacks Investment Research lowered PDL BioPharma from a “buy” rating to a “hold” rating in a report on Monday, January 8th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. PDL BioPharma presently has an average rating of “Hold” and an average price target of $3.33.
About PDL BioPharma
PDL BioPharma, Inc seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company’s segments include income generating assets and product sales.
Receive News & Ratings for PDL BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDL BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.